Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Hsp90 inhibition in B cell acute lymphoblastic leukemia overcomes resistance to JAK2 inhibitors.

• Publication year

  2011

• Venue

  Journal of Experimental Medicine

• Publication date

  2011-11-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20111694PMID 22271575PMCID 3280877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

  2011cited by this paper
• Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

  2011cited by this paper
• SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

  2011cited by this paper
• Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias

  2011cited by this paper
• Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

  2011cited by this paper
• The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

  2011cited by this paper
• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  2011cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

  2010influential reference
• Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.

  2010cited by this paper
• Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

  2010cited by this paper
• Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.

  2010cited by this paper
• A structure-guided approach to creating covalent FGFR inhibitors.

  2010cited by this paper
• Rearrangement of CRLF 2 is associated with mutation of JAK kinases , alteration of IKZF 1 , Hispanic / Latino ethnicity , and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia *

  2010cited by this paper
• HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

  2010cited by this paper
• Cooperative epigenetic modulation by cancer amplicon genes.

  2010cited by this paper
• SAFETY AND EFFICACY

  2010cited by this paper
• Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

  2010cited by this paper
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Recent developments on JAK2 inhibitors: a patent review

  2010cited by this paper
• Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

  2010cited by this paper
• Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

  2009cited by this paper
• Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

  2009influential reference
• The heat shock protein 90 inhibitor IPI‐504 induces apoptosis of AKT‐dependent diffuse large B‐cell lymphomas

  2009cited by this paper
• A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas

  2009influential reference
• Therapeutic potential of JAK2 inhibitors.

  2009cited by this paper
• JAK mutations in high-risk childhood acute lymphoblastic leukemia

  2009influential reference
• Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS‐T) a necessary or useful diagnostic category?

  2009cited by this paper
• Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia

  2009cited by this paper
• Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

  2009influential reference
• SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling

  2009cited by this paper
• AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines.

  2009cited by this paper
• Rearrangement of CRLF 2 in B-progenitor – and Down syndrome – associated acute lymphoblastic leukemia

  2009cited by this paper
• Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

  2008cited by this paper
• Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

  2008cited by this paper
• NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

  2008cited by this paper
• NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

  2008cited by this paper
• JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

  2008cited by this paper
• The JAK kinase inhibitor CP‐690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

  2008cited by this paper
• Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

  2008influential reference
• Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

  2007cited by this paper
• Jak2: normal function and role in hematopoietic disorders.

  2007cited by this paper
• A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry

  2007cited by this paper
• Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

  2007cited by this paper
• Heat shock protein 90: The cancer chaperone

  2007influential reference
• Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.

  2007influential reference
• MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

  2006influential reference
• GenePattern 2.0

  2006cited by this paper
• Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

  2006cited by this paper
• The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

  2006cited by this paper
• Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

  2006cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003influential reference
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Recent developments in dea : the mathematical programming approach to frontier analysis

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms

  2025cites this paper
• Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

  2025cites this paper
• A Comprehensive Review of Somatic and Germline Biomarkers Associated with Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: From Biological Significance to Precision Medicine Opportunities

  2025cites this paper
• The Mechanisms of Resistance to JAK Inhibitors in Lymphoid Leukemias: A Scoping Review of Evidence from Preclinical Models and Case Reports

  2025influential citation
• PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond

  2024cites this paper
• Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

  2024cites this paper
• Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies.

  2024cites this paper
• New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.

  2023cites this paper
• Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches

  2023cites this paper
• A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance

  2023cites this paper
• Efficacy of Different Immunological Approaches Targeting CD22 for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia: A Research Protocol

  2022cites this paper
• Pre-Clinical Assessment of MCL-1 as a Therapeutic Target in T-Cell Lymphomas

  2022cites this paper
• Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives

  2022cites this paper
• JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies

  2022cites this paper
• BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia

  2022cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• TYK2 Activating Alterations in Acute Lymphoblastic Leukemia: Novel Driver Oncogenes with Potential Avenues for Precision Medicine?

  2021influential citation
• Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.

  2021cites this paper
• Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

  2021cites this paper
• Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia

  2021cites this paper
• HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias

  2021cites this paper
• Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms

  2021cites this paper
• Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms

  2021cites this paper
• Acute Leukemias

  2021cites this paper
• Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia

  2021cites this paper
• The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer

  2020cites this paper
• Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.

  2020cites this paper
• Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL

  2020cites this paper
• Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms

  2020cites this paper
• BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy.

  2020cites this paper
• Ph-Like ALL: Diagnosis and Management

  2020cites this paper
• Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms

  2020cites this paper
• Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation

  2019cites this paper
• SOHO State of the Art Updates and Next Questions: Myelofibrosis.

  2019cites this paper
• Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy

  2019cites this paper
• Mutagenic players in ALL progression and their associated signaling pathways.

  2019cites this paper
• JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

  2018influential citation
• Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

  2018cites this paper
• Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.

  2018cites this paper
• Challenges and implications of genomics for T-cell lymphomas.

  2018cites this paper
• Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia

  2018cites this paper
• SOHO State‐of‐the‐Art Update and Next Questions: MPN

  2018cites this paper
• SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia

  2018cites this paper
• Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents

  2018cites this paper
• Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

  2018cites this paper
• Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.

  2017cites this paper
• How is the Ph-like signature being incorporated into ALL therapy?

  2017cites this paper
• Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.

  2017cites this paper
• Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death

  2017cites this paper
• Investigational Janus kinase inhibitors in development for myelofibrosis

  2017cites this paper
• [Research progress in Ph-like childhood acute lymphoblastic leukemia].

  2017cites this paper
• Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.

  2017cites this paper
• Philadelphia chromosome-like acute lymphoblastic leukemia.

  2017cites this paper
• The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL

  2017cites this paper
• A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.

  2017cites this paper
• Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition

  2017cites this paper
• Novel Therapies for Myelofibrosis

  2017cites this paper
• Traffic lights for ruxolitinib.

  2017cites this paper
• Ph-like acute lymphoblastic leukemia.

  2016cites this paper
• Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms

  2016cites this paper
• Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

  2016cites this paper
• The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

  2016cites this paper
• LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.

  2016cites this paper
• Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.

  2016cites this paper
• JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia

  2016cites this paper
• Overcoming Resistance in Patient-Derived Xenograft Models of BCR-ABL-Rearranged Acute Lymphoblastic Leukemia

  2016influential citation
• HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.

  2016cites this paper
• Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms

  2016cites this paper
• Regulation of Survival by IKKE in Inflammatory Breast Cancer Involves EpCAM

  2016cites this paper
• Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

  2016influential citation
• The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

  2016cites this paper
• AWARD NUMBER: W81XWH-13-1-0029 TITLE: Regulation of Survival by IKKe in Inflammatory Breast Cancer Involves EpCAM PRINCIPAL INVESTIGATOR: Thanh Barbie, M.D. CONTRACTING ORGANIZATION: Dana-Farber Cancer Institute

  2016cites this paper
• Stress-induced phosphoprotein-1 maintains the stability of JAK2 in cancer cells

  2016cites this paper
• Estudo do perfil genético de pacientes com Neoplasias Mieloproliferativas (NMP) cromossomo Filadélfia negativo

  2016cites this paper
• Clinical potential of pacritinib in the treatment of myelofibrosis

  2015cites this paper
• A HYPER TH17 RESPONSE CONNECTS THE PSORIASIS-ASSOCIATED ACT1 VARIANT TO SKIN INFLAMMATION

  2015cites this paper
• Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

  2015influential citation
• Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

  2015cites this paper
• JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications

  2015cites this paper
• HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia

  2015cites this paper
• HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms

  2015cites this paper
• Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

  2015influential citation
• Dual Functions in Response to Heat Stress and Spermatogenesis: Characterization of Expression Profile of Small Heat Shock Proteins 9 and 10 in Goat Testis

  2015cites this paper
• Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance

  2015cites this paper
• Identification of a Dual Inhibitor of Janus Kinase 2 ( JAK 2 ) and p 70 Ribosomal S 6 Kinase 1 ( S 6 K 1 ) Pathways *

  2015cites this paper
• Structure-guided selection of specificity determining positions in the human Kinome

  2015cites this paper
• Novel insights into the biology and treatment of chronic myeloproliferative neoplasms*

  2015cites this paper
• Fever and the thermal regulation of immunity: the immune system feels the heat

  2015cites this paper
• Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways*

  2015cites this paper
• CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

  2015cites this paper
• PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.

  2015cites this paper
• Novel therapies for myelofibrosis

  2015cites this paper
• PU-H 71 : An improvement on nature ’ s solutions to oncogenic Hsp 90 addiction

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Contribution of chaperones to STAT pathway signaling.

  2014cites this paper
• Novel myelofibrosis treatment strategies: potential partners for combination therapies

  2014cites this paper
• Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines

  2014cites this paper
• HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

  2014cites this paper
• Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model.

  2014cites this paper
• A method for screening and validation of resistant mutations against kinase inhibitors.

  2014cites this paper